Volume 2, Issue 1 (Winter 2017)                   J Res Urol 2017, 2(1): 1-8 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Amirzargar H, Amirzargar M A, Ebrahimi M, Baharvand H, Basiri A, Solgi G, et al . Efficacy of Bone Marrow Stem-Cell Infusion and Survival of Renal Transplantation in Non-relative Transplant Recipients ​. J Res Urol. 2017; 2 (1) :1-8
URL: http://urology.umsha.ac.ir/article-1-45-en.html
Urology & Nephrology Researh Center, Hamadan University of Medical Sciences, Hamadan, Iran , dr_Amirzargar@yahoo.com
Abstract:   (1280 Views)
Background and Objective: The present study investigated the effect of donor stem cells on improving transplant survival and reducing the need to use repressive drugs in patients with kidney transplant.
Methods: The clinical trial included two groups of patients. A total of five patients received stem cells prepared from the peripheral blood (18–23 ×109 cells/case) four times before and after the transplantation (intervention group). This was in addition to renal transplantation from an unrelated donor. The control group comprised eight patients who received renal transplantation from non-relative recipients. The level of peripheral blood chimerism was determined by the incompatibility of HLA and using a PCR-flow cytometry combined method in the first, third, and twelfth-month after the transplantation.
Results: CMV infection was present in 12.5% of patients in the control group whereas 37.5% had urinary tract infection and 12.5% had digestive problems. Five out of eight patients in the control group acutely rejected the transplant in comparison with two out of five patients in the intervention group. Additionally, in each group, a case of exponential rejection was reported. The evaluation of peripheral active chimerism in two patients with stable transplant and normal function showed that peripheral chimerism was detectable up to 3 months after transplantation. No sign of transplant rejection was observed in the presence of chimerism.
Conclusion: Injection of donor stem cells can cause peripheral chimerism in kidney transplant recipients. The injection has a direct relation to the improvement of transplant function and increases in its survival.
Full-Text [PDF 704 kb]   (600 Downloads)    
Type of Study: Applicable | Subject: Laparoscopy
Received: 2017/12/2 | Accepted: 2018/01/17 | Published: 2018/01/17

1. Monaco AP, Liegeois A, Wood ML, Clark AW. Active enhancement of tissue allografts with antilymphocyte serum and bone marrow. Adv Nephrol Necker Hosp. 1975;5:135-72. [PubMed]
2. Monaco AP, Wood ML, Maki T, Gozzo JJ, DeFazio S. The use of donor-specific antigen for the induction of immunologic unresponsiveness to experimental and clinical allografts. Transplant Proc. 1988;20(1 Suppl 1):122-30. [PubMed]
3. Elwood ET, Larsen CP, Maurer DH, Routenberg KL, Neylan JF, Whelchel JD, et al. Microchimerism and rejection in clinical transplantation. Lancet. 1997;349(9062):1358-60. [PubMed]
4. Ciancio G, Garcia-Morales R, Mathew J, Carreno M, Burke GW, Ricordi C, et al. Donor bone marrow infusions are tolerogenic in human renal transplantation. Transplant Proc. 2001;33(1-2):1295-6. [PubMed]
5. Siemionow M, Nasir S. Chimerism and bone marrow based therapies in transplantation. Microsurgery. 2007;27(5):510-21. [DOI] [PubMed]
6. Starzl TE, Demetris AJ, Trucco M, Zeevi A, Ramos H, Terasaki P, et al. Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation. 1993;55(6):1272-7. PMC2953386. [PubMed]
7. Bluth MH, Reid ME, Manny N. Chimerism in the immunohematology laboratory in the molecular biology era. Transfus Med Rev. 2007;21(2):134-46. [DOI] [PubMed]
8. Mengel M, Jonigk D, Wilkens L, Radermacher J, von Wasielewski R, Lehmann U, et al. Chimerism of metanephric adenoma but not of carcinoma in kidney transplants. Am J Pathol. 2004;165(6):2079-85. [DOI] [PubMed]
9. De Pauw L, Abramowicz D, Donckier V, Kornreich A, Destrée M, Demoor F et al. Isolation and infusion of donor CD34+ bone marrow cells in cadaver kidney transplantation. Nephrol Dial Transplant. 1998;13(1):34–6. https://doi.org/10.1093/ndt/13.1.34 PMID:9481712 [DOI] [PubMed]
10. Yasumoto A, Yamada K, Sablinski T, LeGuern C, Sykes M, Sachs DH. Mechanism of tolerance following class II gene transduction of autologous swine bone marrow. Transplant Proc. 1997;29(1-2):1132. [DOI] [PubMed]
11. Brennan DC, Mohanakumar T, Flye MW. Donor-specific transfusion and donor bone marrow infusion in renal transplantation tolerance: a review of efficacy and mechanisms. Am J Kidney Dis. 1995;26(5):701–15. [DOI] [PubMed]
12. Garcia-Morales R, Carreno M, Mathew J, Cirocco R, Zucker K, Ciancio G et al. Continuing observations on the regulatory effects of donor-specific bone marrow cell infusions and chimerism in kidney transplant recipients. Transplantation. 1998 ;65(7):956–65. [DOI] [PubMed]
13. Garcia-Morales R, Carreno M, Mathew J, Zucker K, Cirocco R, Ciancio G et al. The effects of chimeric cells following donor bone marrow infusions as detected by PCR-flow assays in kidney transplant recipients. J Clin Invest. 1997;99(5):1118–29. [DOI] [PubMed]
14. Ciancio G, Burke GW, Garcia-Morales R, Suzart K, Rosen A, Ricordi C et al. Effect of living-related donor bone marrow infusion on chimerism and in vitro immunoregulatory activity in kidney transplant recipients. Transplantation. 2002;74(4):488–96. [DOI] [PubMed]
15. Barber WH, Mankin JA, Laskow DA, Deierhoi MH, Julian BA, Curtis JJ et al. Long-term results of a controlled prospective study with transfusion of donor-specific bone marrow in 57 cadaveric renal allograft recipients. Transplantation. 1991;51(1):70–5. [DOI] [PubMed]
16. Mathew JM, Garcia-Morales RO, Carreno M, Jin Y, Fuller L, Blomberg B et al. Immune responses and their regulation by donor bone marrow cells in clinical organ transplantation. Transpl Immunol. 2003 Jul-Sep;11(3-4):307–21. [DOI] [PubMed]
17. Garcia-Morales R, Esquenazi V, Zucker K, Gomez CI, Fuller L, Carreno M et al. An assessment of the effects of cadaver donor bone marrow on kidney allograft recipient blood cell chimerism by a novel technique combining PCR and flow cytometry. Transplantation. 1996;62(8):1149–60. [DOI] [PubMed]
18. Trivedi H, Shah V, Shah P, Darji P, Sane A, Vanikar A et al. High dose DBMC associated tolerance in live-related renal allograft recipients. Transplant Proc. 2000;32(7):2001–2. [PubMed]
19. Trivedi H, Vanikar A, Shah V, Mehta A, Shah S, Shah T et al. Mega dose unfractionated donor bone marrow-derived cell infusion in thymus and periphery-an integrated clinical approach for tolerance in living related renal allografts. Transplant Proc. 2003;35(1):203–6. [DOI] [PubMed]
20. Trivedi HL, Shah VR, Shah PR, Sane AS, Vanikar AV, Trivedi VB et al. Megadose approach to DBMC infusion-induced allograft hyporesponsiveness in living-related renal allograft recipients. Transplant Proc. 2001;33(1-2):71–6. [DOI] [PubMed]
21. Trivedi HL, Shah VR, Vanikar AV, Gera D, Shah PR, Trivedi VB et al. High-dose peripheral blood stem cell infusion: a strategy to induce donor-specific hyporesponsiveness to allografts in pediatric renal transplant recipients. Pediatr Transplant. 2002 ;6(1):63–8. [DOI] [PubMed]
22. Trivedi HL, Vanikar AV, Modi PR, Shah VR, Vakil JM, Trivedi VB et al. Allogeneic hematopoietic stem-cell transplantation, mixed chimerism, and tolerance in living related donor renal allograft recipients. Transplant Proc. 2005;37(2):737–42. [DOI] [PubMed]
23. Trivedi HL, Vanikar AV, Vakil JM, Shah VR, Modi PR, Trivedi VB. A strategy to achieve donor-specific hyporesponsiveness in cadaver renal allograft recipients by donor haematopoietic stem cell transplantation into the thymus and periphery. Nephrol Dial Transplant. 2004;19(9):2374–7. [DOI] [PubMed]

Add your comments about this article : Your username or Email:

Send email to the article author

© 2019 All Rights Reserved | Journal of Research in Urology

Designed & Developed by : Yektaweb